Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 701–800 of 1,000
Pharmacotherapy of bone metastases in breast cancer patients – an update
Jacobs, C. M., Simos, D., Addison, C., Ibrahim, M. F. K., & Clemons, M. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.903925 · Cited by 12
Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys
Matheny, J. B., Torres, A. M., Ominsky, M. S., & Hernandez, C. J. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0258-3 · Cited by 15
Management der Osteoporose nach Fragilitätsfrakturen
Gosch, M., Stumpf, U. C., Kammerlander, C., Böcker, W., Heppner, H.-J., & Wicklein, S. (2018) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1355-7 · Cited by 17
Zhao, B., Chen, A., Wang, H., Cui, J., Sun, Y. J., Xu, L., & Mao, Y. (2020) · International Urology and Nephrology · doi:10.1007/s11255-020-02495-x · Cited by 14
The Risk of Bone Fractures in Post-Poliomyelitis Patients Transitioning to Middle Adulthood
Mamlok, S. R., Cantrell, D., Or, K., Markus, E., Shapira, A., Benbassat, C. A., Ish‐Shalom, S., & Koren, R. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0102 · Cited by 13
Genetics and Genomics of SOST: Functional Analysis of Variants and Genomic Regulation in Osteoblasts
Martínez‐Gil, N., Roca‐Ayats, N., Cozar, M., García‐Giralt, N., Ovejero, D., Nogués, X., Grinberg, D., & Balcells, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020489 · Cited by 14
Eudy, R., Gastonguay, M. R., Baron, K., & Riggs, M. M. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12013 · Cited by 14
Haynes, K., Tseng, H., Kneissel, M., Glant, T. T., Brown, M. A., & Thomas, G. P. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0823-8 · Cited by 12
Lewiecki, E., Baron, R., Bilezikian, J., Gagel, R. E., Leonard, M., Leslie, W., Mcclung, M., & Miller, P. D. (2015) · Journal of clinical densitometry · doi:10.1016/j.jocd.2015.11.003 · Cited by 12
Self-citationThe 2024 Guidelines for Osteoporosis - Korean Society of Menopause
Lee, D. O., Hong, Y. H., Cho, M. K., Choi, Y. S., Chun, S., Chung, Y., Hong, S. H., Hwang, K. R., Kim, J., Kim, H., et al. (2024) · Journal of Menopausal Medicine · doi:10.6118/jmm.24000 · Cited by 14
A bone adhesive enhances osteoporotic fracture repair by regulating bone homeostasis
Su, S., Xie, J., Gao, J., Liu, S., Dong, X., Li, J., Gao, Z. F., Chen, K., & Liu, W. (2024) · NPG Asia Materials · doi:10.1038/s41427-024-00539-7 · Cited by 12
REGγ is essential to maintain bone homeostasis by degrading TRAF6, preventing osteoporosis
Du, Y., Chen, H., Zhou, L., Guo, Q., Gong, S., Feng, S., Guan, Q., Shi, P., Lv, T., Guo, Y., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405265121 · Cited by 11
Ferrari, S., Betah, D., Feldman, R. G., Langdahl, B. L., Oates, M. K., Timoshanko, J., Wang, Z., & Dhaliwal, R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae862 · Cited by 11
Self-citationEffects of Bisphosphonates and Denosumab on Dental Implants: A Systematic Review With Meta‐Analysis
Lin, L., Ren, Y., Wang, X., & Yao, Q. (2025) · Oral Diseases · doi:10.1111/odi.15373 · Cited by 11
Etani, Y., Noguchi, T., Yukishima, T., Kobayakawa, T., Kashii, M., Okamura, G., Goshima, A., Hirao, M., Miura, T., Kurihara, T., et al. (2025) · Bone · doi:10.1016/j.bone.2025.117627 · Cited by 11
Musculoskeletal responses to spaceflight: mechanisms, countermeasures, and key gaps
Roberts, B. M., Deane, C. S., Szewczyk, N. J., Fajardo, V. A., Maden‐Wilkinson, T., & Bagley, J. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00649.2025 · Cited by 15
Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation
Wang, L., Tao, X., Jiang, H., Ding, S., Zhang, N., Yang, X., Wang, S., Zhang, Y., Li, N., Li, H., et al. (2026) · Bone Research · doi:10.1038/s41413-026-00511-x · Cited by 12
Möckel, L. (2020) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-020-01784-5 · Cited by 11
Myeloma Bone Disease: The Osteoblast in the Spotlight
Andrews, R. E., Brown, J. E., Lawson, M. A., & Chantry, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173973 · Cited by 11
Self-citation(2021) · PubMed Central · Cited by 11
Self-citationKobayakawa, T., Miyazaki, A., Takahashi, J. A., & Nakamura, Y. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.02.002 · Cited by 13
D’Onofrio, B., di Lernia, M., Stefano, L. D., Bugatti, S., Montecucco, C., & Bogliolo, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092341 · Cited by 11
Xu, C., Ji, G., Chen, X., Yan, L., Liang, T., Liu, J., & Wang, F. (2022) · Connective Tissue Research · doi:10.1080/03008207.2022.2135507 · Cited by 11
Antisclerostin Effect on Osseointegration and Bone Remodeling
Couto, B. A. D. A., Fernandes, J. C. H., Saavedra-Silva, M., Roca, H., CASTILHO, R. M., & Fernandes, G. V. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041294 · Cited by 14
Romosozumab-associated medication-related osteonecrosis of the jaw
Palla, B., Anderson, J., Miloro, M., Moles, S., & Callahan, N. (2023) · Oral and Maxillofacial Surgery Cases · doi:10.1016/j.omsc.2023.100318 · Cited by 10
Clinical Aspects of Fracture Healing: An Overview
Liu, J. X., Buza, J. A., & Leucht, P. (2015) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9196-7 · Cited by 11
Inhibitors of sclerostin: emerging concepts
Drake, M. T., & Farr, J. N. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000073 · Cited by 13
Mechanobiologie und Knochenstoffwechsel: Klinische Bedeutung für die Frakturbehandlung
Haffner‐Luntzer, M., Liedert, A., & Ignatius, A. A. (2015) · Der Unfallchirurg · doi:10.1007/s00113-015-0102-z · Cited by 13
The Crucial Role of the WNT System in Bone Remodelling
Grigorie, D., & Lerner, U. H. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.90 · Cited by 13
Alterations in bone turnover markers in patients with noncardio-embolic ischemic stroke
Mathold, K., Wanby, P., Brudin, L. H., Von, S.-P., & Carlsson, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207348 · Cited by 11
Sclerostin and its role as a bone modifying agent in periodontal disease
Ashifa, N., Viswanathan, K., Sundaram, R., & Srinivasan, S. (2021) · Journal of Oral Biosciences · doi:10.1016/j.job.2021.04.002 · Cited by 13
Rapp, K., Lamb, S. E., Roigk, P., Becker, C., Konnopka, C., König, H., Peter, R. S., Rothenbacher, D., & Büchele, G. (2022) · BMC Medicine · doi:10.1186/s12916-021-02226-8 · Cited by 11
Hattori, K., & Kanayama, Y. (2024) · Modern Rheumatology · doi:10.1093/mr/roae008 · Cited by 12
Thouverey, C., Apostolides, P., Brun, J., Caverzasio, J., & Ferrari, S. (2024) · JCI Insight · doi:10.1172/jci.insight.176558 · Cited by 12
Akbar, A., Zaheer, A., Kharal, M. M., Komel, A., Khan, M. H., Ahsan, A., & Singh, A. K. (2025) · Medicine · doi:10.1097/md.0000000000041605 · Cited by 16
Osteoblast-specific expression of Panx3 is dispensable for postnatal bone remodeling
Yorgan, T. A., Peters, S., Amling, M., & Schinke, T. (2019) · Bone · doi:10.1016/j.bone.2019.06.008 · Cited by 12
Ogata, M., Ushimaru, S., Fujishima, R., Sumi, H., Shiizaki, K., & Tominaga, N. (2022) · Bone Reports · doi:10.1016/j.bonr.2022.101639 · Cited by 10
Quek, Y. Y., Cheng, L. J., Ng, Y. X., Hey, H. W. D., & Wu, X. V. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad121 · Cited by 11
Osteoporosis: Investigations and Monitoring
Panchagnula, R., & Amarnath, S. S. (2023) · Indian Journal of Orthopaedics · doi:10.1007/s43465-023-01019-w · Cited by 10
Vithran, D. T. A., Essien, A. E., Rahmati, M., Opoku, M., Yon, D. K., Sánchez, G. F. L., Koyanagi, A., Smith, L., Shin, J. I., Xiao, W., et al. (2024) · EFORT Open Reviews · doi:10.1530/eor-23-0205 · Cited by 10
Tominaga, R., Ikenoue, T., Ishii, R., Niihata, K., Aita, T., Okuda, T., Shimizu, S., Kurita, N., & Taguri, M. (2025) · Bone · doi:10.1016/j.bone.2025.117523 · Cited by 10
Bariatric Surgery and Bone Loss: Do We Need to Be Concerned?
Brzozowska, M. M., Sainsbury, A., Eisman, J. A., & Baldock, P. A. J. (2014) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-014-9162-9 · Cited by 12
Tanaka, S., ADACHI, T., Kuroda, T., Nakamura, T., Shiraki, M., Sugimoto, T., Takeuchi, Y., Saito, M., & Bilezikian, J. P. (2014) · Bone Research · doi:10.1038/boneres.2014.43 · Cited by 11
Delgado‐Calle, J., & Bellido, T. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3141 · Cited by 10
Butscheidt, S., Rolvien, T., Vettorazzi, E., & Frieling, I. (2018) · Bone · doi:10.1016/j.bone.2018.06.022 · Cited by 11
Sims, N. A., & Martin, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00004-x · Cited by 13
Kaupp, S. M., Horan, D. J., Lim, K., Feldman, H. A., Robling, A. G., Warman, M. L., & Jacobsen, C. M. (2019) · Bone · doi:10.1016/j.bone.2019.115084 · Cited by 12
Collins, C. J., Yang, B., Crenshaw, T. D., & Ploeg, H. (2020) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2020.104253 · Cited by 13
TANAKA, M., Idei, M., Sakaguchi, H., Kato, R., Sato, D., Sawanobori, K., Kawarasaki, S., Hata, T., Yoshizaki, A., Nakamura, M., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14749 · Cited by 11
The role of bone‐modifying agents in myeloma bone disease
Lu, H., Pundole, X., & Lee, H. C. (2021) · JBMR Plus · doi:10.1002/jbm4.10518 · Cited by 12
Novel therapeutic targets in myeloma bone disease
Webb, S. L., & Edwards, C. M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12742 · Cited by 12
Sclerosteosis caused by a novel nonsense mutation of SOST in a consanguineous family
He, W., Chen, C., Pan, C., Zhang, M., Yu, X., Wang, D. W., & Hu, S. (2015) · Clinical Genetics · doi:10.1111/cge.12655 · Cited by 11
Emerging therapeutic concepts for muscle and bone preservation/building
Compston, J. E. (2015) · Bone · doi:10.1016/j.bone.2015.04.013 · Cited by 11
Sclerostin expression in skeletal sarcomas
Shen, J., Meyers, C. A., Shrestha, S., Singh, A. S., LaChaud, G., Nguyen, V., Asatrian, G., Federman, N. C., Bernthal, N. M., Eilber, F. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.016 · Cited by 11
Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume
Morse, A., Cheng, T. L., Schindeler, A., McDonald, M. M., Mohanty, S. T., Kneissel, M., Krämer, I., & Little, D. G. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0420-6 · Cited by 10
Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications
Bover, J., Ureña, P., Láiz, A. M., Torregrosa, J., Rodríguez-García, M., Castro-Alonso, C., Górriz, J. L., Benito, S., López‐Báez, V., Cora, M. J. L., et al. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.10.008 · Cited by 19
Modeling craniofacial and skeletal congenital birth defects to advance therapies
Neben, C. L., Roberts, R. R., Dipple, K. M., Merrill, A. E., & Klein, O. D. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw171 · Cited by 10
‘Bone Health—Across a Woman's Lifespan’
Stokes, G., Herath, M., Samad, N., Trinh, A., & Milat, F. (2025) · Clinical Endocrinology · doi:10.1111/cen.15203 · Cited by 18
Role of Sclerostin in Cardiovascular System
Zhang, N., Wang, L., Li, X., Yang, X., Tao, X., Jiang, H., Yu, Y., Liu, J., Yu, S., Ma, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104552 · Cited by 10
Skeletal Adaptation to Mechanical Strain: A Key Role in Osteoporosis
Sugiyama, T., Kim, Y. T., & Oda, H. (2015) · Springer eBooks · doi:10.1007/978-4-431-55778-4_1 · Cited by 9
Ouyang, Y., Chen, S., Wan, T., Zheng, G., & Sun, G. (2021) · Medicine · doi:10.1097/md.0000000000024839 · Cited by 9
Atualização do Tratamento Medicamentoso da Osteoporose
Oliveira, L. G., Carneiro, M. L. R. G., de Souza, M. P. G., de Souza, C. G., de Moraes, F. B., & de Camargo, F. L. (2021) · Revista Brasileira de Ortopedia · doi:10.1055/s-0040-1714219 · Cited by 41
Harahap, I., Kuligowski, M., SCHMIDT, M. T., Brzozowska, A., & Suliburska, J. (2022) · Acta Scientiarum Polonorum Technologia Alimentaria · doi:10.17306/j.afs.1059 · Cited by 9
Inose, H., Kato, T., Tomizawa, S., Ariga, A., Motoyoshi, T., Fukushima, K., Takahashi, K., Yoshii, T., & Okawa, A. (2022) · Bone Reports · doi:10.1016/j.bonr.2022.101635 · Cited by 9
Oue, T., Shimizu, T., Asano, T., Shimodan, S., Ishizu, H., Arita, K., & Iwasaki, N. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01079-y · Cited by 9
Gong, W., Li, M., Zhao, L., Wang, P., Wang, X., Wang, B., Liu, X., & Tu, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1215233 · Cited by 9
Yu, S., Huang, W., Zhang, H., Guo, Y., Zhang, B., Zhang, G., & Lei, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116414 · Cited by 10
Morales, S., Díez‐Pérez, A., Olmos, J. M., Nogués, X., Henríquez, M. S., Díaz Curiel, M., Pérez‐Castrillón, J. L., Pérez-Cano, R., Torrijos, A., Jódar, E., et al. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.08.007 · Cited by 13
The systemic effects of sclerostin overexpression using ΦC31 integrase in mice
Zhang, D., Park, B. M., Kang, M., Nam, H. J., Kim, E. J., Bae, C. H., & Lim, S. K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.178 · Cited by 11
Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop
Ward, L. M., Kinnett, K., Bonewald, L. F., Adachi, J. D., Bachrach, L. K., Bellido, T., Brotto, M. A. P., Bonewald, L. F., Donovan, J. M., Hoffman, E. P., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.05.012 · Cited by 10
Practical management of fracture risk among peri- and postmenopausal women
Blank, R. D. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.09.038 · Cited by 10
Advances in Target-Specific Therapy for Osteoporosis
Watts, N. B., & Bilezikian, J. P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1065 · Cited by 9
Coupling: The Influences of Immune and Bone Cells
Sims, N., Martin, T., & Quinn, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00010-4 · Cited by 8
Sclerostin: More than a bone formation brake
Rauch, F., & Adachi, R. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4628 · Cited by 9
Jin, X., Zhou, B., & Zhang, D. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2017.0204 · Cited by 10
Albiol, L., Cilla, M., Pflanz, D., Krämer, I., Kneissel, M., Duda, G. N., Willie, B. M., & Checa, S. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2018.0012 · Cited by 9
Guo, T., Xing, Y., Zhu, H.-Y., Yang, L., Liu, G., & Qiao, X. (2019) · Bioscience Reports · doi:10.1042/bsr20190432 · Cited by 11
RetractedCathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?
Chapurlat, R. D. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.09.008 · Cited by 9
Romosozumab rescues impaired bone mass and strength in a murine model of diabetic kidney disease
Kohler, R. K., Segvich, D. M., Reul, O. N., Metzger, C. E., Allen, M. R., & Wallace, J. M. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101774 · Cited by 9
Towards a personalized approach in senolytic trials
Khosla, S., Monroe, D. G., & Farr, J. N. (2025) · Nature Aging · doi:10.1038/s43587-025-00964-5 · Cited by 13
Kwon, J.-W., Moon, S.-H., Suk, K., Park, S.-Y., Kim, H., Park, S.-R., Kim, N., & Lee, B. (2025) · Neurospine · doi:10.14245/ns.2550774.387 · Cited by 8
Critical illness and bone metabolism: where are we now and what is next?
Yun, C., Kang, F.-X., & Wang, X. (2022) · European journal of medical research · doi:10.1186/s40001-022-00805-w · Cited by 9
Harousseau, J., & Mohty, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6 · Cited by 9
Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
Trajanoska, K., & Rivadeneira, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556610 · Cited by 9
Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease
Adhikari, M., & Delgado‐Calle, J. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00679-7 · Cited by 10
Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody
Morrell, A. E., Robinson, S. T., Ke, H. Z., Holdsworth, G., & Guo, X. E. (2021) · Bone · doi:10.1016/j.bone.2021.115967 · Cited by 8
Cejka, D., Wakolbinger, R., Zitt, E., Fahrleitner‐Pammer, A., Amrein, K., Dimai, H. P., & Muschitz, C. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00989-0 · Cited by 9
Relevance of Wnt signaling for osteoanabolic therapy
Yorgan, T. A., & Schinke, T. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-22 · Cited by 11
Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown
Sedaghati, B., Jahroomishirazi, R., Starke, A., Hacker, M. C., & Schulz‐Siegmund, M. (2016) · Cells Tissues Organs · doi:10.1159/000444634 · Cited by 8
Effects of Drugs on Bone Quality
Imbert, L., & Boskey, A. L. (2016) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-016-9220-6 · Cited by 9
Schlecht, S. H., Smith, L., Ramcharan, M., Bigelow, E. M. R., Nolan, B. T., Mathis, N. J., Cathey, A. L., Manley, E., Menon, R., McEachin, R. C., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3093 · Cited by 9
Urinary N-Telopeptide Can Predict Pseudarthrosis After Anterior Cervical Decompression and Fusion
Steinhaus, M. E., Hill, P. S., Yang, J., Feuchtbaum, E., Bronheim, R. S., Prabhakar, P., Lafage, V., Carlson, B. B., Saville, P. A., Albert, T. J., et al. (2018) · Spine · doi:10.1097/brs.0000000000002935 · Cited by 8
Yamamoto, T., Hasegawa, T., de Freitas, P. H. L., Hongo, H., Zhao, S., Yamamoto, T., Nasoori, A., Abe, M., Maruoka, H., Kubota, K., et al. (2021) · Biomedical Research · doi:10.2220/biomedres.42.161 · Cited by 9
Amniotic fluid volume at 41 weeks and infant outcome.
Lam, H., Leung, W.-C., Lee, C.-P., & Lao, T. T.-H. (2006) · PubMed · Cited by 10
Building Better Bones with Biologics — A New Approach to Osteoporosis?
Rosen, C. J., & Ingelfinger, J. R. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611863 · Cited by 8
Cardiovascular Safety and Romosozumab—The Plot Thickens
Farr, J. N. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae313 · Cited by 8
Teraguchi, M., Kitayama, Y., Yamada, Y., Nakamoto, Z., Yamaoka, Y., & Yamada, H. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf096 · Cited by 7
Wang, L., Tao, X., Zhang, N., Yang, X., Jiang, H., Li, X., Wang, S., Ding, S., Yu, S., Zhang, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202518735 · Cited by 16
The potential use of antisclerostin therapy in chronic kidney disease – mineral and bone disorder
Costa, A. G., Bilezikian, J. P., & Lewiecki, E. M. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000133 · Cited by 8
Romosozumab for the treatment of postmenopausal women at high risk of fracture
Geusens, P., Appelman‐Dijkstra, N. M., Lems, W. F., & van den Bergh, J. P. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2152320 · Cited by 7
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.